Press Release

U.S. Biosimilars Market to surge at 54.7% CAGR and Hit US$ 17,696.0 Mn by 2026

U.S. Biosimilars Market 2019 Robust Expansion by Top Key Manufactures | Worldwide Overview by Size, Share, Trends, Segments

The U.S. Biosimilars Market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” The Market is projected to reach US$ 17,696.0 Mn by 2026. The report provides valuable insights into the drivers influencing growth of the market. As per the report, The Market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990

Some of the other players operating in the U.S. biosimilars market are

  • Hoffmann-La Roche Ltd.,
  • AbbVie Inc.,
  • Merck & Co.,
  • Celltrion Inc.,
  • Coherus BioSciences, Inc.,
  • Teva Pharmaceutical Industries Ltd.,
  • Eli Lilly and Company

Increased Research and Development Initiatives to Drive the Market

Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.

Get [email protected] https://www.fortunebusinessinsights.com/enquiry/check-discount/u-s-biosimilars-market-100990

Table of content:

  1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

  1. Executive Summary
  2. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

  1. Key Insights

4.1 Prevalence of Key Disease Associated with the Scope – U.S., 2018

4.2 New Product Launch

4.3 Pipeline Analysis

4.4 Regulatory Scenario

4.5. Reimbursement Scenario

4.6. Patent Snapshot of Biologics

4.6 Key Industry Developments – Partnerships, Mergers & Acquisitions

  1. U.S. Biosimilars Market Analysis, Insights and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Drug Class

5.2.1 Filgrastim & Pegfilgrastim

5.2.2 Monoclonal Antibodies

5.2.2 Others

5.3. Market Analysis, Insights and Forecast – By Disease Indication

5.3.1 Cancer

5.3.2 Autoimmune Diseases

5.3.2.1 Arthritis

5.3.2.2 Psoriasis

5.3.2.3 Neutropenia

5.3.2.4 Others

5.3.3 Others

5.4. Market Analysis, Insights and Forecast – By Distribution Channel

5.4.1 Hospital Pharmacy

5.4.2 Retail Pharmacy

5.4.3 Online Pharmacy

Order Full [email protected] https://www.fortunebusinessinsights.com/checkout-page/100990

Autoimmune Diseases Segment Projected to Dominate the Market in the U.S.

The U.S. biosimilars market is classified into three segments, namely, by distribution channel, by disease indication, and by drug class. By distribution channel, the market is grouped into online pharmacy, hospital pharmacy, and retail pharmacy. In terms of disease indication, the market is divided into cancer and autoimmune diseases such as arthritis, neutropenia, psoriasis, and others. In 2018, the autoimmune diseases held a market share of 92.0%. The segment is anticipated to remain in the leading position the market during the forecast period. Factors like increasing adoption of biosimilars, rise in the prevalence of autoimmune diseases, and availability of limited drugs are likely to boost the segment. The Centers of Disease Control and Prevention declared that approximately 26% adults are estimated to have arthritis by 2040. This in turn, will increase the demand for biosimilars to treat arthritis. Moreover, treatment of cancer is expensive in the U.S. Combined with this, constant investments in research and development and rise in the adoption of sedentary lifestyle are projected to favor growth of the cancer segment throughout the forecast period in the U.S.

More Trending Topics From Fortune Business [email protected]

Agricultural Biologicals Market Size, Growth by Type, Mode of Application, Industry Analysis, Top Companies and Global Report Forecast to 2026

Revenue Cycle Management Outsourcing Market 2019 |Global Industry Analysis by Trends, Growth and Forecast by 2026 | Latest Research Report by Fortune Business Insights

Tags

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close